Grants and Contributions:

Back to search

Title:

ARP- A sword and shield immune fusokine against solid malignancies and virus infections

Agreement Number:

993313

Agreement Value:

$75,000.00

Agreement Date:

Jul 20, 2022 - May 1, 2023

Description:

Combination therapies have been evaluated in the clinic to achieve multi-functionality. However, some drug combination therapies can have multiple outcomes that may not be synergistic, causing side effects. In this project, the aim is to investigate the immunostimulatory properties of the drug product in cancer patient's immune cells, identify biomarkers in immune cells from cancer patients at different disease stages, and assess the anti-cancer efficacy of the product in a cancer disease model as a standalone treatment and in combination with other known therapy.

Organization:

National Research Council Canada

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:

Montreal, Quebec, CA H4A 2R2

Reference Number:

172-2022-2023-Q2-993313

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

784721318

Recipient Type:

For-profit organization

Additional Information:

This agreement has been amended 1 time(s). The end date of this agreements has been modified by 66 days.

Amendment Date

Jan 13, 2023

Recipient's Operating Name:

Cura Therapeutics

Recipient's Legal Name:

10493279 Canada Inc.

Federal Riding Name:

Notre-Dame-de-Grâce--Westmount

Federal Riding Number:

24053

Program:

Industrial Research Assistance Program – Contributions to Firms

Program Purpose:

Coverage:

IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.

NAICS Code:

3254

Amendments:

See Amendments